Person: KARAKURT, SAİT
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
KARAKURT
First Name
SAİT
Name
10 results
Search Results
Now showing 1 - 10 of 10
Publication Metadata only Does preexisting immuncompromised status prevent mortality in COVID-19 patients: friend or foe?(2022-09-01) VEZİR, DUYGU; KOCAKAYA, DERYA; MERCANCI, ZEYNEP; KARAKURT, SAİT; Vezir D., Yildizeli S. O., KOCAKAYA D., Mercanci Z., Balcan B., Cinar C., Eryuksel E., KARAKURT S.Publication Open Access Outcome of solid and cavitary pulmonary nodules in rheumatoid arthritis patients— case series(2022-01-01) AKSOY, AYSUN; BOZKURTLAR, EMİNE; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; İNANÇ, GÜZİDE NEVSUN; KOCAKAYA, DERYA; AKSOY A., KOCAKAYA D., Yalçinkaya Y., BOZKURTLAR E., KARAKURT S., Eryüksel E., İnanç N.© TÜBİTAK.Background/aim: Rheumatoid pulmonary nodule can be detected in up to 32% of rheumatoid arthritis (RA) patients and approximately one-third of nodules may cavitate. We aimed to evaluate characteristics of patients with RA developing cavitary pulmonary nodular (CPN) lesions under disease-modifying antirheumatic drugs (DMARDs), follow-up of both cavitary and solid nodules, and their outcome with the treatment. Materials and methods: RA patients who presented with CPN lesions during follow-up were recruited retrospectively in this case series analysis. Total numbers and mean diameters of cavitary and solid nodules in each thorax computed tomography (CT) have been determined and followed up by two experienced pulmonary physicians. Moreover, changes in treatment after the development of the CPN lesions and characteristics of cavitary nodules were collected. Results: Eleven patients with CPN lesions were reported. At the time of CPN diagnosis, more patients were taking leflunomide than methotrexate (81% vs 19%). Half of the patients were receiving biologic therapy and only 18% were taking anti-TNF drugs. After a median of 24 (3–65) months of follow-up, the regression of CPN lesions was determined in 45% (5/11) of patients. Four of these 5 (80%) patients were switched to a treatment regimen without leflunomide and three of them to nonanti-TNF biologic treatment or targeted synthetic DMARDs (tocilizumab, tofacitinib, and rituximab). Conclusion: CPN lesions seen in RA patients are often pulmonary manifestations of the underlying disease; however, one must rule out malignancies or infections. If lesions progress under DMARDs, it is advised to discontinue synthetic DMARDs (LEF/MTX) and switch to another biological DMARD with different modes of action.Publication Open Access Tuberculosis menengitis during pregnancy: a case report(2019-05-17) KORTEN, VOLKAN; ESİM BÜYÜKBAYRAK, ESRA; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; Saçar Kübüç K., Nazlı İ., Korten V., Esim Büyükbayrak E., Karakurt S., Eryüksel S. E.Publication Open Access Reliability and validity of the Turkish translation of the beliefs about medicines questionnaire (bmq-t) in patients with behçet’s disease(2018-10-01) ARIKAN, HÜSEYİN; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; ARIKAN H., Duman D., Kargın F., ERGİN G., Horne R., KARAKURT S., ERYÜKSEL S. E.Publication Open Access Association of the changes in pulmonary artery diameters with clinical outcomes in hospitalized patients with COVID-19 infection: A cross-sectional study(2022-01-01) ILGIN, CAN; KARAKURT, SAİT; Selcuk A., ILGIN C., KARAKURT S.Objective: Enlarged pulmonary artery diameter (PAD) can be associated with mortality risk in coronavirus disease 2019 (COVID-19) patients. Our aim is to find the factors that cause changes in PAD and the relationship between radiological findings and clinical outcomes in COVID-19 patients.Publication Open Access Esophagus Dilation and Quality of Life in Adults with Scleroderma and Concomitant Obstructive Sleep Apnea(2024-04-01) KARAKURT, SAİT; DİRESKENELİ, RAFİ HANER; Yakut T., Cinar C., KARAKURT S., DİRESKENELİ R. H., Yalcinkaya Y., Peker Y.(1) Background: Systemic sclerosis (SSc) is a rare systemic disease, which often affects the esophagus, leading to dilation and complications such as dysphagia and reflux. Obstructive sleep apnea (OSA) is a chronic condition with recurrent episodes of upper airway collapsibility and is known to impair quality of life (QoL). The primary aim of this study was to investigate the occurrence of esophagus dilation in patients with SSc and concomitant OSA and, further, to address the impact of these conditions on QoL. (2) Methods: In this cross-sectional cohort study, 62 consecutive patients with SSc underwent chest computer tomography (CT) and home sleep apnea testing. The OSA diagnosis was based on AHI ≥ 15 events/h. The QoL was quantified using the short-form (SF)-36 questionnaire. The patients were dichotomized as high- vs. low-esophageal-diameter groups, based on the median cut-off values. (3) Results: The mean age was 48 ± 11 years; 58 (93.5%) were female; the mean BMI was 26.7 ± 5.0 kg/m2. The median esophageal diameter was 17.47 mm. A larger esophageal diameter was more frequently associated with the diffuse cutaneous subtype of SSc (p = 0.002) and significantly higher Warrick scores (p < 0.001), indicating more severe pulmonary fibrosis. There was a significant linear correlation between the Warrick score and the esophageal diameter (standardized β coefficient 0.544 [%95 confidence interval 0.250–0.609]; p < 0.001). In the subgroup analysis, the patients with both OSA and enlarged esophageal diameter experienced a significant decline in QoL, particularly in the domains of physical functioning, role physical, general health, role emotional, and vitality. (4) Conclusions: While OSA was not directly associated with enlarged esophageal diameter in patients with SSc, those with both OSA and enlarged esophageal diameter exhibited a significant decline in QoL. These findings suggest that the presence of OSA may exacerbate the adverse effects of esophageal dilation on QoL in SSc patients. Our results underline the importance of considering both gastrointestinal and sleep-related aspects in SSc management to enhance patient QoL.Publication Metadata only Clinical Pharmacist-Led Medication Review in Hospitalized Confirmed or Probable Patients with COVID-19 During the First Wave of COVID-19 Pandemic(2024-01-01) ÜNDER, DUYGU; ENVER, CÜNEYD; DEMİRCİ, MUHAMMED YASİR; AYHAN, YUNUS EMRE; ÖZGAN, BETÜL; İLERLER, ENES EMİR; OKUYAN, BETÜL; ERTÜRK ŞENGEL, BUKET; KOCAKAYA, DERYA; SİLİ, ULUHAN; TİGEN, ELİF; KARAKURT, SAİT; KORTEN, VOLKAN; SANCAR, MESUT; ÜNDER D., ENVER C., DEMİRCİ M. Y., AYHAN Y. E., ÖZGAN B., İLERLER E. E., OKUYAN B., ERTÜRK ŞENGEL B., KOCAKAYA D., SİLİ U., et al.Objectives: Drug-related problems (DRPs) result in serious problems among hospitalized patients, high rates of morbidity and mortality, and increased healthcare costs. This study aimed to identify DRPs by clinical pharmacist-led medication review in hospitalized probable patients with coronavirus disease-2019 (COVID-19) during the first wave of the COVID-19 pandemic. Materials and Methods: This retrospective cross-sectional study was conducted at the COVID-19 inpatient services of a tertiary university hospital in Türkiye for 3 months (between March 2020 and June 2020) and included hospitalized confirmed or probable COVID-19 patients. The World Health Organization and Turkish Ministry of Health Guidelines case definitions were used to define confirmed and probable COVID-19 patients. Six clinical pharmacy residents provided medication review services during their education and training. DRPs were classified based on the Pharmaceutical Care Network Europe V9.00. The physician’s acceptance rate of clinical pharmacists’ recommendations was assessed. Results: Among 202 hospitalized patients with probable or confirmed COVID-19, 132 (65.3%) had at least one drug-related problem. Two hundred and sixty-four DRPs were identified. Drug selection (85.6%) and dose selection (9.2%) were the most common causes of these problems. Among the 80 clinical pharmacist interventions, 48.8% were accepted by the physicians. Conclusion: Clinical pharmacists identified a significant number of DRPs during the COVID-19 pandemic, particularly those related to drug interactions and drug safety, such as adverse drug reactions. This study highlights the importance of detecting and responding to DRPs in the COVID-19 pandemic.Publication Open Access Malign melanom, endobronşial metastaz(2009-04-09) KOCAKAYA, DERYA; OLGUN YILDIZELİ, ŞEHNAZ; ERYÜKSEL, SEMİHA EMEL; ÇELİKEL, ÇİĞDEM; KARAKURT, SAİT; Kocakaya D., Abul Y., Olgun Yıldızeli Ş., Eryüksel S. E., Tosuner Z., Yazıcı Z., Çelikel Ç., Karakurt S.Amaç: Malign melanoma melanositlerin malign transfomayonu sonucu gelişir.Pulmoner metastazını pulmoner arterlere ulaşan tümör embolileri yoluyla yapar.Endobronşial yayılımlı malign melonom vakaları sınırlı sayıdadır. Gereç ve Yöntem: Nadir görülen endobronşial yayılım yapmış bronkoskopi ile tanı koyduğumuz vakamızı sunduk. Bulgular: 42 yaşında bayan hasta nefes darlığı şikaye ile başvurdu. 2006 da tanı konan sır a konjenital dev nevüs tanısı mevcu u.5 paket/yıl sigara hikayesi mevcu u. Fizik muayenede bel bölgesinde 25x15 cm boyularında yaklaşık tüm lumbar bölgeyi kaplayan gluteal bölgeye de yayılan dev nevüsü mevcu u. Vücu a özellikle sır a ve saçlı deride birden fazla çok sayıda nevüsler izlendi. Nevüslerde renk değişikliği tariflemiyordu. Sır aki dev nevüste kalınlaşma belir yordu. Solunum sistemi muayenesi doğaldı.Aksiller ele gelen 1x2 cm lik lenfadenopa si mevcu u. PA akciğer grafisinde sol hilar bölgede düzensizlik ve dansite ar şı mevcu u. Toraks BT’de sol üst lobda 40x30 mm kitlesel lezyon mevcu u. Bronkoskopide sol akciğer üst lob girişinde nevüs tarzında siyahımsı mukozadan kabarık endobronşial lezyon izlendi. Alınan bronkoskopik biyopsi, rça ve bronkoalveolar lavaj materyalleri malign melonom ile uyumlu geldi. Sonuç: Malign melanoma bağlı endobronşial metastaz nadirdir. Literatürde 1966-2002 yılları arası yapılmış geniş taramada 204 akciğer dışı kaynaklı endobronşial metastaz vakası saptanmış olup bunları sırasıyla meme(%35), böbrek(%17), kolon ve rektum(%15) oluşturmaktadır.. Deri kanseri vakaları sadece 9 vaka olup , 7’si malign melanom kökenli saptanmış r. Tanıda primer akciğer kanserinden ayırtetmek için bronkoskopi şar r. Malign melannomaya bağlı endobronşial metastazı olgumuzu literatürde nadir görülmEsi nedeniyle sunduk.Publication Metadata only Increased D-dimer is associated with disease progression and increased mortality in Turkish COVID-19 patients(2023-05-31) MERCANCI, ZEYNEP; ILGIN, CAN; OLGUN YILDIZELİ, ŞEHNAZ; KOCAKAYA, DERYA; BALCAN, MEHMET BARAN; KARAKURT, SAİT; ERYÜKSEL, SEMİHA EMEL; Mercanci Z., ILGIN C., Yildizeli S. O., KOCAKAYA D., Balcan B., Sengel B. E., KARAKURT S., Eryuksel E.Objective: Coagulopathy is thought to play an important role in the development of severe COVID-19. High D-dimer levels have been reported in Chinese cohort studies. However, ethnicity has significant implications for thrombotic risk. Our aim in this study is to determine the effect of D-dimer measurements on disease prognosis and mortality in Turkish patients with COVID-19. Patients and Methods: The study was designed retrospectively. Patients over the age of 18 who were admitted to our hospital were included in the study. Results: The study included 226 patients. According to the World Health Organization staging, 75(33.2%) patients, according to the staging of Siddiqi et al., 67 (29.7%) patients progressed. In the ROC analysis performed to predict mortality, AUC value for D-dimer was found to be 82.25% (95%CI 74.8%-89.71%). When the cut-off value for D-dimer was accepted as ≥3.25mg/L, specificity was 94.15%, correctly classified rate 88.5%, positive likelihood ratio as (LR):5.69, negative LR:0.71. Conclusion: As a result, similar to the Chinese cohorts, elevated D-dimer measurements increase disease progression and mortality in Turkish patients with COVID-19. D-dimer levels of 3.25 mg/L and above, strongly determine the risk of increased mortality in the Turkish Caucasian ethnic group.Publication Open Access Assessment of drug-induced electrolyte disorders in intensive care units: a multicenter observational study(2024-01-01) İLERLER, ENES EMİR; KARAKURT, SAİT; SANCAR, MESUT; Ayhan Y. E., İLERLER E. E., Sosyal D., BEKTAY M. Y., KARAKURT S., DAŞKAYA H., KARAASLAN K., SANCAR M.Objective: Electrolyte disorder (ED) is frequently encountered critically ill patients during admission or admission to the intensive care unit (ICU). This study aimed to determine the frequency of ED encountered in ICU patients to evaluate the relationship of ED with drugs. Methods: This prospective, multicenter study was conducted in the medical and anesthesiology ICUs of two training and research hospitals and included patients with at least one ED during admission or hospitalization in the ICUs. The relationship between ED and the drug was evaluated by calculating the logistic probabilistic method scale (LPMS) and the expert panel’s evaluation. The correlation between EDs and LPMS was determined using Kendal tau. A binary logistic regression model was preferred in the analysis of factors related to ED. Statistical significance was set as p < 0.05. Results: A total of 117 patients were included in the study. A total of 165 EDs were detected, including at least one in 88 (75.2%) patients. According to the expert panel, 61 (21.7%) of EDs were drug-related, whereas according to the LPMS, 111 (39.6%) (p < 0.001). Mortality (50% vs. 13.7%) and mechanical ventilation rates (52.2% vs. 17.2%) were significantly higher in patients with ED (p < 0.001). Patients with ED had 8.352 times higher odds of exhibiting mortality (OR: 8.352, %95 CI: 1.598–43.648, p: 0.012) and need mechanical ventilation with higher odds of 3.229 (OR: 3.229 95% CI: 0.815–12.787 p: 0.045). Patient who required enteral or parenteral feeding were associated with an increased likelihood of exhibiting ED (respectively OR: 30.057, %95 CI: 2.265–398.892, p: 0.01, OR: 5.537, %95 CI: 1.406–21.800, p: 0.014). Conclusion: EDs are very common in the ICU. Dysnatremia was detected more commonly in other EDs. It has also been found that patients with ED are more often under mechanical ventilation, have more prolonged hospitalizations, and have higher mortality rates than patients without ED. The suitability of LPMS for assessing ED-drug relationships in the ICU context is questioned. KEYWORDS: intensive care unit, electrolyte disorder, clinical pharmacist, drug-related problems, patient safety